News Express: Novel drug developed by UM and CUHK wins gold medal at International Exhibition of Inventions Geneva
新聞快訊：澳大與港中大聯合研發藥物於國際發明展獲金獎
趙琦（左）和其博士生符勝煜
Zhao Qi (left) and his PhD student Fu Shengyu
澳大與港中大聯合研發藥物於國際發明展獲金獎
由澳門大學健康科學學院副教授趙琦與香港中文大學助理教授梁錦堂領導的研究團隊共同研發的治療血癌抗體藥物“Fc工程化CD9抗體”，在“第50屆日內瓦國際發明展”中脫穎而出，獲評審團嘉許金獎。
該研究旨在解決現有CD9抗體治療血癌時常見的血栓副作用問題。研究團隊成功開發出Fc工程化抗體，有效降低血小板毒性，同時維持對難治性白血病的治療效果，有望克服CD9靶向治療發展的瓶頸。
日內瓦國際發明展是全球最大規模的創新展覽，所有參賽作品均經過由135位專家組成的國際評審團嚴格評估。今屆發明展共展出來自38個國家和地區超過1,050項發明，匯聚全球創新意念。
欲瀏覽官網版可登入以下連結:
https://www.um.edu.mo/zh-hant/news-and-press-releases/press-release/detail/61129/
Novel drug developed by UM and CUHK wins gold medal at International Exhibition of Inventions Geneva
A collaborative research led by Zhao Qi, associate professor in the Faculty of Health Sciences (FHS) at the University of Macau (UM), and Leung Kam Tong, assistant professor at The Chinese University of Hong Kong (CUHK), has been awarded a Gold Medal with Congratulations of the Jury at the 50th International Exhibition of Inventions Geneva for the development of the ‘Fc-engineered CD9 antibody for blood cancers’.
The research aims to address the thrombosis side effects commonly associated with existing CD9 antibody treatments for leukaemia. The research team has successfully developed an Fc-engineered antibody that effectively reduces platelet toxicity while maintaining therapeutic efficacy against refractory leukaemia. This breakthrough has the potential to overcome bottlenecks in the development of CD9-targeted therapies.
The International Exhibition of Inventions Geneva is the world’s largest exhibition of inventions, where all entries undergo rigorous evaluation by an international jury of 135 experts. This year’s exhibition showcased over 1,050 inventions from 38 countries and regions, representing a diverse array of innovative ideas from around the world.
To read the news on UM’s official website, please visit the following link:
https://www.um.edu.mo/news-and-press-releases/press-release/detail/61129/